Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis has initiated a phase I clinical trial to evaluate the safety, tolerability and bodily reaction to XL820, an orally administered, anti-cancer compound. The trial will be conducted in patients with solid tumors for whom there are no available therapies known to prolong survival.
Subscribe to our email newsletter
The company has been encouraged to initiate the clinical phase of development by positive results in preclinical studies. XL820 has exhibited dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia. Also, in an animal model of more advanced malignancy, significant tumor regression was seen.
“This is the second of four compounds we expect to enter into phase I clinical trials this year. I am incredibly proud of the diligent work of our clinical development team. Their extraordinary ability to execute is essential to the success of Exelixis as we move towards reaching the goal of providing novel therapies to cancer patients,” said Dr George Scangos, president and CEO of Exelixis.
The trial will be conducted at two highly regarded centers, one being the CTRC (Cancer Therapy and Research Center) Institute for Drug Development (IDD) in San Antonio, Texas.